A summary of important studies in breast cancer from 2024 by Yakup Ergün

Yakup Ergün, Medical Oncologist at Antalya City Hospital, posted on X:

“What happened in breast cancer in 2024? A summary of important studies.”

Here are All the Important Studies about Brest Cancer in 2024.

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Authors: S. Loibl, O. Metzger, S.J. Mandrekar, C. Mundhenke, S. Seiler, P. Valagussa, A. DeMichele, E. Lim, D. Tripathy, E.P. Winer, C. Huang, L. Carey, P. Francis, K.D. Miller, M.P. Goetz, A. Prat, S. Loi, I. Krop, L. Gianni, E.M. Ciruelos

Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial

Authors: Toralf Reimer, Angrit Stachs, Kristina Veselinovic, Thorsten Kühn, Jörg Heil, Silke Polata, Frederik Marmé, Thomas Müller, Guido Hildebrandt, David Krug, Beyhan Ataseven, Roland Reitsamer, Sylvia Ruth, Carsten Denkert, Inga Bekes, Dirk-Michael Zahm, Marc Thill, Michael Golatta, Johannes Holtschmidt, Michael Knauer, Valentina Nekljudova, Sibylle Loibl, Bernd Gerber

Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial

Authors: Icro Meattini, Maria Carmen De Santis, Luca Visani, Marta Scorsetti, Alessandra Fozza, Bruno Meduri, Fiorenza De Rose, Elisabetta Bonzano, Agnese Prisco, Valeria Masiello, Eliana La Rocca, Ruggero Spoto, Carlotta Becherini, Gladys Blandino, Luca Moscetti, Riccardo Ray Colciago, Riccardo A Audisio, Etienne Brain, Saverio Caini, Marije Hamaker, Orit Kaidar-Person, Matteo Lambertini, Livia Marrazzo, Calogero Saieva, Tanja Spanic, Vratislav Strnad, Sally Wheelwright, Philip M P Poortmans, Lorenzo Livi

Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial

Authors: E Shelley Hwang, Terry Hyslop, Thomas Lynch, Marc D Ryser, Anna Weiss, Anna Wolf, Kelsey Norris, Meredith Witten, Lars Grimm, Stuart Schnitt, Sunil Badve, Rachel Factor, Elizabeth Frank, Deborah Collyar, Desiree Basila, Donna Pinto, Mark A Watson, Robert West, Louise Davies, Jenny L Donovan, Ayako Shimada, Yutong Li, Yan Li, Antonia V Bennett, Shoshana Rosenberg, Jeffrey Marks, Eric Winer, Marc Boisvert, Armando Giuliano, Kelsey E Larson, Kathleen Yost, Priscilla F McAuliffe, Amy Krie, Nina Tamirisa, Lisa A Carey, Alastair M Thompson, Ann H Partridge

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Authors: Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga, Philippe Aftimos, Cristina Saura, Joyce O’Shaughnessy, Nadia Harbeck, Lisa A Carey, Giuseppe Curigliano, Antonio Llombart-Cussac, Elgene Lim, María de la Luz García Tinoco, Joohyuk Sohn, André Mattar, Qingyuan Zhang, Chiun-Sheng Huang, Chih-Chiang Hung, Jorge Luis Martinez Rodriguez, Manuel Ruíz Borrego, Rikiya Nakamura, Kamnesh R Pradhan, Christoph Cramer von Laue, Emily Barrett, Shanshan Cao, Xuejing Aimee Wang, Lillian M Smyth, François-Clément Bidard

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

Authors: Galina Velikova, Linda Jane Williams, Sarah Willis, J Michael Dixon, Juliette Loncaster, Matthew Hatton, Jacqueline Clarke, Ian H Kunkler, Nicola S Russell

De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial

Authors: Xiu-Chun Chen, De-Chuang Jiao, Jiang-Hua Qiao, Cheng-Zheng Wang, Xian-Fu Sun, Zhen-Duo Lu, Lian-Fang Li, Chong-Jian Zhang, Min Yan, Ya Wei, Bo Chen, Yue-Qing Feng, Miao Deng, Ming-De Ma, Jennifer K Plichta, You-Wen He, Zhen-Zhen Liu

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer

Authors: Gabe S Sonke, Annemiek van Ommen-Nijhof, Noor Wortelboer, Vincent van der Noort, Astrid C P Swinkels, Hedwig M Blommestein, Cristina Guerrero Paez, Linda Mol, Aart Beeker, Karin Beelen, Lisanne C Hamming, Joan B Heijns, Aafke H Honkoop, Paul C de Jong, Quirine C van Rossum-Schornagel, Christa van Schaik-van de Mheen, Jolien Tol, Cathrien S Tromp-van Driel, Suzan Vrijaldenhoven, A Elise van Leeuwen-Stok, Inge R Konings, Agnes Jager

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Authors: Nicholas C Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J Stout, Katherine E Hutchinson, Jennifer L Schutzman, Chunyan Song, Komal L Jhaveri

Ribociclib plus Endocrine Therapy in Early Breast Cancer

Authors: Dennis Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas McAndrew, Bozena Kukielka-Budny, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, Peter A Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Manuel Ruiz-Borrego, Sherene Loi, Binghe Xu, Sara Hurvitz, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan P Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel Hortobagyi

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Authors: Tina Cascone, William N William Jr, Annikka Weissferdt, Cheuk H Leung, Heather Y Lin, Apar Pataer, Myrna C B Godoy, Brett W Carter, Lorenzo Federico, Alexandre Reuben, Md Abdul Wadud Khan, Hitoshi Dejima, Alejandro Francisco-Cruz, Edwin R Parra, Luisa M Solis, Junya Fujimoto, Hai T Tran, Neda Kalhor, Frank V Fossella, Frank E Mott, Anne S Tsao, George Blumenschein Jr, Xiuning Le, Jianjun Zhang, Ferdinandos Skoulidis, Jonathan M Kurie, Mehmet Altan, Charles Lu, Bonnie S Glisson, Lauren Averett Byers, Yasir Y Elamin, Reza J Mehran, David C Rice, Garrett L Walsh, Wayne L Hofstetter, Jack A Roth, Mara B Antonoff, Humam Kadara, Cara Haymaker, Chantale Bernatchez, Nadim J Ajami, Robert R Jenq, Padmanee Sharma, James P Allison, Andrew Futreal, Jennifer A Wargo, Ignacio I Wistuba, Stephen G Swisher, J Jack Lee, Don L Gibbons, Ara A Vaporciyan, John V Heymach, Boris Sepesi

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O’Shaughnessy

Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis

Authors: Guy Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A Hurvitz, Shanu Modi, Fabrice Andre, Ian E Krop, Xavier Gonzàlez Farré, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R Osborne, Rashmi K Murthy, Lorenzo Gianni, Toshimi Takano, Yali Liu, Jillian Cathcart, Caleb Lee, Christophe Perrin

Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial

Authors: Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D Baird, Yeon Hee Park, Peter S Hall, Timothy Perren, Robert C Stein, László Mangel, Jean-Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortes, Andrew Foxley, Elza C de Bruin, Robert McEwen, Daniel Stetson, Brian Dougherty, Shah-Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C Turner

Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases

Authors: Jana de Boniface, Tove Filtenborg Tvedskov, Lisa Rydén, Robert Szulkin, Toralf Reimer, Thorsten Kühn, Michalis Kontos, Oreste D Gentilini, Roger Olofsson Bagge, Malin Sund, Dan Lundstedt, Matilda Appelgren, Johan Ahlgren, Sophie Norenstedt, Fuat Celebioglu, Helena Sackey, Inge Scheel Andersen, Ute Hoyer, Per F Nyman, Eva Vikhe Patil, Elinore Wieslander, Henrik Dahl Nissen, Sara Alkner, Yvette Andersson, Birgitte V Offersen, Leif Bergkvist, Jan Frisell, Peer Christiansen

Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Authors: Alexios Matikas, Volker Möbus, Richard Greil, Anne Andersson, Günther G Steger, Michael Untch, Tommy Fornander, Per Malmström, Sabine Schmatloch, Hemming Johansson, Mats Hellström, Yvonne Brandberg, Michael Gnant, Sibylle Loibl, Theodoros Foukakis, Jonas Bergh

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT

Authors: Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C Wolff, Katherine Reeder-Hayes, Hope S Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, P Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta C Liu, Kathryn J Ruddy, Adrienne G Waks, Michelle DeMeo, Harold J Burstein, Ann H Partridge, Patrizia Dell’Orto, Leila Russo, Emma Krause, Daniel J Newhouse, Busem Binboğa Kurt, Elizabeth A Mittendorf, Bryan Schneider, Aleix Prat, Eric P Winer, Ian E Krop, Sara M Tolaney

AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer

Authors: Aditya Bardia, Javier Cortes, Sara A Hurvitz, Suzette Delaloge, Hiroji Iwata, Zhi-Ming Shao, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Joyce O’Shaughnessy

A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy

Authors: Pier Franco Conte, Maria Vittoria Dieci, Giancarlo Bisagni, Peter Schmid, Vittoria Fotia, Federico Piacentini, Michelino De Laurentiis, Adolfo G. Favaretto, Stefano Tamberi, Giulia Valeria Bianchi, Claudio Zamagni, Saverio Cinieri, Domenico C. Corsi, Lucia Del Mastro, Antonella Ferro, Alessandra Gennari, Marta Mion, Antonino Musolino, Gian Luca De Salvo, Valentina Guarneri

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H Barrios, Joyce A O’Shaughnessy, Hans Wildiers, Jean-Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock-Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano

Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial

Authors: Kevin Kalinsky, Giampaolo Bianchini, Erika P. Hamilton, Stephanie L. Graff, Kyong Hwa Park, Rinath Jeselsohn, Umut Demirci, Miguel Martin, Rachel M. Layman, Sara A. Hurvitz, Sarah L Sammons, Peter A. Kaufman, Montserrat Muñoz, Ling-Ming Tseng, Holly Knoderer, Bastien Nguyen, Yanhong Zhou, Elizabeth Ravenberg, Lacey M Litchfield, Seth Andrew Wander

DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC

Authors: Fabrice Andre, Erika P. Hamilton, Sherene Loi, Carey K. Anders, Peter Schmid, Daniil Stroyakovskiy, Rafael Villanueva, Jose Luiz Pedrini, Dinesh Chandra Doval, Bogdan Zurawski, Shin-Cheh Chen, Sarice Renee Boston, Adam Konpa, Barbara Pierotti, Giulia Fabbri, Komal L. Jhaveri

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial

Authors: Javier Cortés, Sara A. Hurvitz, Seock-Ah Im, Hiroji Iwata, Giuseppe Curigliano, Sung-Bae Kim, Joanne W.Y. Chiu, Jose L. Pedrini, Wei Li, Kan Yonemori, Giampaolo Bianchini, Sherene Loi, Giuliano S. Borges, Xian Wang, Thomas Bachelot, Shunsuke Nakatani, Shahid Ashfaque, Zhengkang Liang, Anton Egorov, Erika Hamilton

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

Authors: Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, Yesim Eralp, Yoon Sim Yap, Seock-Ah Im, Julie Rihani, Erhan Gokmen, Ahmed El Bastawisy, Nuri Karadurmus, Yueh Ni Lim, Chun Sen Lim, Le Thanh Duc, Wei-Pang Chung, K Govind Babu, Konstantin Penkov, James Bowles, Teresa Delgar Alfaro, Jiwen Wu, Melissa Gao, Khemaies Slimane, Nagi S El Saghir